You have no items in your shopping cart.

BKK: Commercializing a New Drug
Goldberg, Rebecca; Matherne, G. Paul Case QA-0909 / Published February 25, 2019 / 13 pages.
Format Price Quantity Select
PDF Download
$6.95
EPUB Download
$6.95
Printed Black & White Copy
$7.25

Product Overview

Dr. Brad Worthington and his friend, Thurman Ballard, needed to commit to one of three possible paths for commercializing BKK, their new combination drug. BKK was a unique, patented formulation of nonopioid anesthesia drugs with an excellent record in practice. Because BKK was based on the synergistic use of three FDA-approved drugs, it could be used without additional approvals. Worthington and Ballard could pursue a New Drug Application, partner with a compounding pharmacy to sell BKK as a premixed product, or opt to sell a convenience kit containing BKK's premeasured components, attractively boxed but not premixed. Each path held risks and promise. Which should they choose?


  • Videos List

  • Overview

    Dr. Brad Worthington and his friend, Thurman Ballard, needed to commit to one of three possible paths for commercializing BKK, their new combination drug. BKK was a unique, patented formulation of nonopioid anesthesia drugs with an excellent record in practice. Because BKK was based on the synergistic use of three FDA-approved drugs, it could be used without additional approvals. Worthington and Ballard could pursue a New Drug Application, partner with a compounding pharmacy to sell BKK as a premixed product, or opt to sell a convenience kit containing BKK's premeasured components, attractively boxed but not premixed. Each path held risks and promise. Which should they choose?

  • Learning Objectives